Wall Street Rallies Behind Lexeo Therapeutics (LXEO)’s Gene Therapy Pipeline
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) is among the Best Get Rich Fast Stocks to Buy Right Now. As of December 24, Lexeo Therapeutics, Inc. (NASDAQ:LXEO) is a consensus buy from all eleven analysts covering the stock. While the target price ranges from $12 to $30, the median price target of $19 translates to an upside potential of 79.92%.
On December 18, Raymond James initiated coverage on Lexeo Therapeutics, Inc. (NASDAQ:LXEO) with a ‘Strong Buy’ rating and a price target of $25, citing solid results from two Phase 1/2 clinical trials and encouraging feedback from the FDA. With that said, the company’s lead candidate, LX2006, an AAV gene therapy for cardiomyopathy associated with Friedreich’s Ataxia, is “well-positioned for success” in its pivotal trial, the analyst asserted.
Photo by National Cancer Institute on Unsplash
Raymond James expects the stock to gain momentum in 2026 following a finalized pivotal protocol with the FDA and initial proof of concept data on LX2020, an unmodeled gene therapy asset. The firm anticipates LX2006 revenue of $14.1 million in FY27, going as high as $805.3 million in FY32.
Earlier on December 10, Cantor Fitzgerald reaffirmed an ‘Overweight’ rating on Lexeo Therapeutics, Inc. (NASDAQ:LXEO), with a price target of $19. The reaffirmation, implying an upside potential of around 80%, is driven by the prospects of the company’s PKP2-ACM program. The analyst highlighted that the market remains focused on Lexeo’s Friedreich’s ataxia program and the PKP2-ACM program appears “under the radar,” particularly as the upcoming data expected in the next month could shift market perception.
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) is a New York-based clinical-stage genetic medicine company. Founded in 2017, the company has a pipeline of programs, including LX2006, LX2020, and LX2021.
While we acknowledge the potential of LXEO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on thebest short-term AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None.
Content Original Link:
" target="_blank">
